Alan H. Jobe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alan H. Jobe has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Machiko Ikegami
Division of Pulmonary Biology, Children's Hospital Medical Center, Cincinnati, Ohio, 45229
5 shared publications- Agustina Mazzoni
Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina
1 shared publication - Ana Garces
IMSALUD, Guatemala City, Guatemala
1 shared publication - Archana Patel
Lata Medical Research Foundation, Nagpur, India
1 shared publication - Bhala Kodkany
KLE University’s Jawaharlal Nehru Medical College, Belgaum, India
1 shared publication Boris W. Kramer
Division of Pulmonary Biology, Children's Hospital Medical Center, Cincinnati, Ohio, 45229
1 shared publication
Latest Publications
- Open Access
- 19 September 2012
- Published by Springer Nature in Reproductive Health
- Vol. 9 (1) , 22
Antenatal corticosteroids trial in preterm births to increase neonatal survival in developing countries: study protocol
Background: Preterm birth is a major cause of neonatal mortality, responsible for 28% of neonatal deaths overall. The administration of antenatal corticosteroids to women at high risk of preterm birth is a powerful perinatal intervention to reduce neonatal mortality in resource rich environments. The effect of antenatal steroids to reduce mortality and morbidity among preterm infants in hospital settings in developed countries with high utilization is well established, yet they are not routinely used in developing countries. The impact of increasing antenatal steroid use in hospital or community settings with low utilization rates and high infant mortality among premature infants due to lack of specialized services has not been well researched. There is currently no clear evidence about the safety of antenatal corticosteroid use for community-level births. Methods: We hypothesize that a multi country, two-arm, parallel cluster randomized controlled trial to evaluate whether a multifaceted intervention to increase the use of antenatal corticosteroids, including components to improve the identification of pregnancies at high risk of preterm birth and providing and facilitating the appropriate use of steroids, will reduce neonatal mortality at 28 days of life in preterm newborns, compared with the standard delivery of care in selected populations of six countries. 102 clusters in Argentina, Guatemala, Kenya, India, Pakistan, and Zambia will be randomized, and around 60,000 women and newborns will be enrolled. Kits containing vials of dexamethasone, syringes, gloves, and instructions for administration will be distributed. Improving the identification of women at high risk of preterm birth will be done by (1) diffusing recommendations for antenatal corticosteroids use to health providers, (2) training health providers on identification of women at high risk of preterm birth, (3) providing reminders to health providers on the use of the kits, and (4) using a color-coded tape to measure uterine height to estimate gestational age in women with unknown gestational age. In both intervention and control clusters, health providers will be trained in essential newborn care for low birth weight babies. The primary outcome is neonatal mortality at 28 days of life in preterm infants. Trial registration: ClinicalTrials.gov. Identifier: NCT01084096
- 19 September 2012
- Published by Springer Nature in Reproductive Health
- Vol. 9 (1) , 22
Open AccessAntenatal corticosteroids trial in preterm births to increase neonatal survival in developing countries: study protocol
Background: Preterm birth is a major cause of neonatal mortality, responsible for 28% of neonatal deaths overall. The administration of antenatal corticosteroids to women at high risk of preterm birth is a powerful perinatal intervention to reduce neonatal mortality in resource rich environments. The effect of antenatal steroids to reduce mortality and morbidity among preterm infants in hospital settings in developed countries with high utilization is well established, yet they are not routinely used in developing countries. The impact of increasing antenatal steroid use in hospital or community settings with low utilization rates and high infant mortality among premature infants due to lack of specialized services has not been well researched. There is currently no clear evidence about the safety of antenatal corticosteroid use for community-level births. Methods: We hypothesize that a multi country, two-arm, parallel cluster randomized controlled trial to evaluate whether a multifaceted intervention to increase the use of antenatal corticosteroids, including components to improve the identification of pregnancies at high risk of preterm birth and providing and facilitating the appropriate use of steroids, will reduce neonatal mortality at 28 days of life in preterm newborns, compared with the standard delivery of care in selected populations of six countries. 102 clusters in Argentina, Guatemala, Kenya, India, Pakistan, and Zambia will be randomized, and around 60,000 women and newborns will be enrolled. Kits containing vials of dexamethasone, syringes, gloves, and instructions for administration will be distributed. Improving the identification of women at high risk of preterm birth will be done by (1) diffusing recommendations for antenatal corticosteroids use to health providers, (2) training health providers on identification of women at high risk of preterm birth, (3) providing reminders to health providers on the use of the kits, and (4) using a color-coded tape to measure uterine height to estimate gestational age in women with unknown gestational age. In both intervention and control clusters, health providers will be trained in essential newborn care for low birth weight babies. The primary outcome is neonatal mortality at 28 days of life in preterm infants. Trial registration: ClinicalTrials.gov. Identifier: NCT01084096
- 1 May 2002
- Published by Springer Nature in Pediatric Research
- Vol. 51 (5) , 662-664
Recruitment and Development of Academic Pediatricians: Departmental Commitments to Promote Success
- 1 May 2002
- Published by Springer Nature in Pediatric Research
- Vol. 51 (5) , 662-664
Recruitment and Development of Academic Pediatricians: Departmental Commitments to Promote Success
- 1 March 2002
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 282 (3) , L411-L420
Intra-amniotic injection of IL-1 induces inflammation and maturation in fetal sheep lung
Antenatal inflammation may be an important triggering event in the pathogenesis of bronchopulmonary dysplasia but may also accelerate fetal lung maturation. We examined the effects of intra-amniotic (IA) interleukin (IL)-1α and IL-1β on maturation of the fetal sheep lung. These cytokine effects were compared with IA endotoxin, a potent proinflammatory stimulus that accelerated lung maturation. Date-bred ewes received 15 or 150 μg recombinant ovine IL-1α or IL-1β or 10 mg Escherichia coli endotoxin by IA injection at 118 days gestation (term = 150 days), and fetuses were delivered at 125 days. IL-1α and IL-1β improved lung function and increased alveolar saturated phosphatidylcholine (Sat PC) and surfactant protein mRNA expression at the higher dose. The maturation response to IL-1α was greater than that to IL-1β, which was similar to endotoxin response. Inflammation was also more pronounced after IL-1α treatment. Only endotoxin animals had residual inflammation of the fetal membranes at 7 days. Lung compliance, lung volume, and alveolar Sat PC were positively correlated with residual alveolar wash leukocyte numbers 7 days after IL-1 treatment, suggesting a link between lung inflammation and maturation.
- 1 March 2002
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 282 (3) , L411-L420
Intra-amniotic injection of IL-1 induces inflammation and maturation in fetal sheep lung
Antenatal inflammation may be an important triggering event in the pathogenesis of bronchopulmonary dysplasia but may also accelerate fetal lung maturation. We examined the effects of intra-amniotic (IA) interleukin (IL)-1α and IL-1β on maturation of the fetal sheep lung. These cytokine effects were compared with IA endotoxin, a potent proinflammatory stimulus that accelerated lung maturation. Date-bred ewes received 15 or 150 μg recombinant ovine IL-1α or IL-1β or 10 mg Escherichia coli endotoxin by IA injection at 118 days gestation (term = 150 days), and fetuses were delivered at 125 days. IL-1α and IL-1β improved lung function and increased alveolar saturated phosphatidylcholine (Sat PC) and surfactant protein mRNA expression at the higher dose. The maturation response to IL-1α was greater than that to IL-1β, which was similar to endotoxin response. Inflammation was also more pronounced after IL-1α treatment. Only endotoxin animals had residual inflammation of the fetal membranes at 7 days. Lung compliance, lung volume, and alveolar Sat PC were positively correlated with residual alveolar wash leukocyte numbers 7 days after IL-1 treatment, suggesting a link between lung inflammation and maturation.
- 1 September 2001
- Published by Elsevier in Clinics in Perinatology
- Vol. 28 (3) , 655-669
BIOLOGY OF SURFACTANT
- 1 September 2001
- Published by Elsevier in Clinics in Perinatology
- Vol. 28 (3) , 655-669
BIOLOGY OF SURFACTANT
- Open Access
- 11 January 2001
- Published by Springer Nature in Respiratory Research
- Vol. 2 (1) , 27-32
Antenatal infection/inflammation and postnatal lung maturation and injury
Chorioamnionitis is frequently associated with preterm deliveries before 30 weeks gestation. Chorioamnionitis correlates both with an increased risk of bronchopulmonary dysplasia and with a decreased risk of respiratory distress syndrome. Both interleukin-1alpha and endotoxin can induce inflammation in the fetal lungs and lung maturation after preterm birth when given by intra-amniotic injection. Inflammation can also result in an arrest of alveolarization, and this lung developmental abnormality is prominent in the lungs of preterm infants that die of bronchopulmonary dysplasia. The mechanisms by which infection/inflammation can have both beneficial and injurious effects on the preterm lung remain to be characterized.
- 11 January 2001
- Published by Springer Nature in Respiratory Research
- Vol. 2 (1) , 27-32
Open AccessAntenatal infection/inflammation and postnatal lung maturation and injury
Chorioamnionitis is frequently associated with preterm deliveries before 30 weeks gestation. Chorioamnionitis correlates both with an increased risk of bronchopulmonary dysplasia and with a decreased risk of respiratory distress syndrome. Both interleukin-1alpha and endotoxin can induce inflammation in the fetal lungs and lung maturation after preterm birth when given by intra-amniotic injection. Inflammation can also result in an arrest of alveolarization, and this lung developmental abnormality is prominent in the lungs of preterm infants that die of bronchopulmonary dysplasia. The mechanisms by which infection/inflammation can have both beneficial and injurious effects on the preterm lung remain to be characterized.
- 1 November 1998
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1408 (2-3) , 218-225
Surfactant protein metabolism in vivo
- 1 November 1998
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1408 (2-3) , 218-225
Surfactant protein metabolism in vivo
- 1 November 1998
- Published by Elsevier in Early Human Development
- Vol. 53 (1) , 81-94
Mechanisms initiating lung injury in the preterm
- 1 November 1998
- Published by Elsevier in Early Human Development
- Vol. 53 (1) , 81-94
Mechanisms initiating lung injury in the preterm